Multi-Regional Clinical Trials for Efficient Development
                     India as a Strategic Geography for 
Multi-Regional Clinical Trials
Country selection can influence the success of a global clinical development 
program. Sponsors need to identify locations that offer suitable patient populations, 
capable investigators, reliable infrastructure, efficient recruitment, and regulatory 
compatibility.
Within this environment, India has become increasingly relevant to Multi-
Regional Clinical Trials. Its role is supported by demographic diversity, clinical 
research capabilities, and an expanding network of experienced research 
professionals.
At the same time, India should be integrated thoughtfully into a global trial 
design.
Why Country Selection Matters
The success of Multi-Regional Clinical Trials depends heavily on the selection of 
participating countries.
Sponsors need to evaluate factors such as disease prevalence, patient 
availability, site infrastructure, investigator experience, regulatory 
requirements, timelines, and operational costs.
A country may offer strong recruitment potential but limited infrastructure for a 
particular protocol. Another may provide advanced infrastructure but have a 
small eligible population.
Therefore, country selection needs to be based on the complete clinical 
development strategy.
India’s Patient Population
India’s large population provides an important advantage for clinical research. The 
country includes diverse demographic and geographic groups and has substantial 
patient populations across several disease areas.
This diversity can support MRCTs seeking broader representation.
However, population size alone does not guarantee recruitment success. 
Eligibility criteria, awareness, referral pathways, site accessibility, and 
investigator engagement all influence actual enrollment.
Clinical Research Infrastructure
India’s clinical research environment has developed considerably. Major hospitals, 
academic institutions, investigators, laboratories, and CROs contribute to 
pharmaceutical and biotechnology research.
Many research teams are familiar with international protocols and Good 
Clinical Practice principles.
For Multi-Regional Clinical Trials, this infrastructure can help sponsors build 
scalable site networks and manage enrollment across multiple locations.
Recruitment and Enrollment
India may serve as an important recruitment geography for MRCTs. High patient 
volumes in certain therapeutic areas can provide opportunities to support 
enrollment targets.
Recruitment planning should begin before site activation. Feasibility teams can 
assess patient availability, referral patterns, competing studies, and historical 
recruitment performance.
This helps sponsors avoid selecting sites based only on theoretical patient 
numbers.
Contribution to Population Diversity
India can also strengthen population diversity in global clinical datasets.
The inclusion of Indian participants provides data from South Asian populations, 
which can complement evidence from North American, European, East Asian, 
and other populations.
This is particularly valuable when treatment response may vary due to 
demographic, genetic, environmental, or healthcare-related factors.
Regulatory Integration
India’s data needs to be integrated into the overall regulatory strategy.
Sponsors should consider how Indian data contributes to the primary objectives of 
the MRCT, planned subgroup analyses, and overall assessment of treatment 
consistency.
The ICH E17 framework provides a useful foundation for considering regional 
factors during MRCT planning.
Operational Considerations
Successful MRCT execution requires consistent processes across participating 
countries.
Differences in medical practices and site workflows can create variability. 
Standardized protocols, investigator training, centralized oversight, quality 
management, and appropriate monitoring can help address these challenges.
Experienced research partners can also support coordination between sponsors, 
investigators, sites, and other stakeholders.
India’s Cost Advantage
Cost efficiency is another factor that can make India attractive for global studies.
Clinical trial operations, site activities, recruitment, and certain research services 
may be more cost-efficient compared with some developed markets.
However, sponsors should avoid choosing countries exclusively on cost. Quality and 
regulatory acceptance must remain central considerations.
A Balanced Global Strategy
The strongest MRCT designs do not depend on one country.
India can provide meaningful contributions in recruitment, diversity, and 
operational execution while other regions contribute additional populations and 
regulatory relevance.
A balanced approach allows sponsors to build a more comprehensive evidence 
package.
India has strong potential as a strategic geography for Multi-Regional Clinical Trials. 
Its patient population, research infrastructure, investigator network, recruitment 
potential, and cost efficiency can contribute to global clinical development.
The key is strategic integration. When India is appropriately balanced with other 
regions, it can help sponsors conduct efficient, diverse, scientifically robust, and 
globally relevant clinical trials